학술논문
1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S1023-S1024
Subject
Language
ISSN
0923-7534